Wednesday’s positive data for the eczema drug tralokinumab has given Leo Pharma a pat on the back for its relatively new gamble on biological medicines.
In three different late-stage studies, the company has achieved all primary and secondary effect goals, which is a result that research director Kim Kjøller calls ”incredibly strong”. Leo Pharma is now counting on using this data as a basis for approval applications to health authorities controlling the large markets in the new year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Senior Project Manager (GMP - Life Science) 
Biomarker Operations Lead 
Communications Consultant 
2 Sales Representatives and Product Specialists 
Nordic Medical Affairs Manager 
Senior QA Specialist 
Industrial Designer- Design Engineer 
IRT Manager, Clinical Drug Supply 
Clinical Trial Manager 
Client Talent Acquisition Specialist 
Senior Chemical Safety Advisor 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Laboratory technician for process development and clinical manufacturing 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Key Account Manager, Europe and Asia